Atara Biotherapeutics Inc (NASDAQ:ATRA)

15.27
Delayed Data
As of Jan 26
 +0.17 / +1.13%
Today’s Change
11.81
Today|||52-Week Range
21.85
-3.11%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$1.2B

Company Description

Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which pioneers the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. also delivers off-the-shelf treatments to patients with high unmet medical need. Its product pipeline includes Tab-cel, ATA188, ATA2271/ATA3271, and ATA3219. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in South San Francisco, CA.

Contact Information

Atara Biotherapeutics, Inc.
611 Gateway Boulevard
South San Francisco California 94080
P:(650) 278-8930
Investor Relations:
(805) 395-9669

Employees

Shareholders

Other institutional57.55%
Mutual fund holders45.33%
Individual stakeholders11.65%

Top Executives

Pascal TouchonPresident, Chief Executive Officer & Director
Joseph NewellChief Operating Officer & Executive Vice President
Utpal KoppikarChief Financial Officer & Senior Vice President
Manher AJ JoshiChief Medical Officer
Jakob DupontGlobal Head-Research & Development